The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.
People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...
A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
Hosted on MSN15h
GLP-1 Drugs and Colonoscopy; GI Symptoms Post-COVID; Identifying High-Risk Barrett'sA systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...
The SYNGAP1 gene, which supports the production of a protein called SynGAP (Synaptic Ras GTPase-Activating Protein), is known ...
Zoetis Inc. $157.52-7.41-4.49% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback